Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02621242 · ClinicalTrials.gov registry record
Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals
A clinical trial, sponsored by University of Washington.
- Completed
- Registry status
- 9
- Enrollment target
NCT02621242: Completed study, sponsored by University of Washington.
NCT02621242 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02621242 has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
As explained in detail in a recently published hypothesis article (Hladik F. A new hypothesis on HIV cure. F1000Research, 4:77 (2015)), the investigators hypothesize that NRTI drugs may reduce the likelihood of HIV eradication by promoting the survival of cells with integrated provirus. In this study, the investigators will test whether daily oral use of two NTRI drugs, tenofovir and emtricitabine (Truvada Pill), induces changes in the upper and lower gut mucosa that are congruent with supporting this hypothesis.
Primary Outcome
Global transcriptome analysis tests for expression changes of any possible gene across the entire human genome in response to Truvada PrEP. The main outcome of such an analysis is the number of genes significantly changing in expression between before and after treatment. We will report that Truvada PrEP up-regulates X number of genes and down-regulates Y number of genes.
Interventions
- PROCEDURE Anoscopy
- DRUG Truvada
- PROCEDURE Upper endoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-12 |
What the finished NCT02621242 record still lists
NCT02621242 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Anoscopy is the first listed.
NCT02621242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02621242 about?
NCT02621242 is a clinical study titled "Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals". As explained in detail in a recently published hypothesis article (Hladik F. A new hypothesis on HIV cure. F1000Research, 4:77 (2015)), the investigators hypothesize that NRTI drugs may reduce the likelihood of HIV eradication by promoting the survival of cells with integrated provirus. In this stud...
What is the current status of trial NCT02621242?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2015-12. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02621242?
The interventions under investigation include: Anoscopy (PROCEDURE), Truvada (DRUG), Upper endoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT02621242?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia